Repligen (RGEN) Set to Announce Earnings on Tuesday

Repligen (NASDAQ:RGEN - Get Free Report) will be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Repligen to post earnings of $0.34 per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Repligen Price Performance

RGEN stock traded up $6.42 during trading hours on Tuesday, hitting $145.95. 373,671 shares of the stock traded hands, compared to its average volume of 657,236. The stock has a 50-day simple moving average of $141.90 and a 200 day simple moving average of $145.52. The company has a market cap of $8.17 billion, a P/E ratio of -3,647.84, a P/E/G ratio of 3.98 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a one year low of $113.50 and a one year high of $211.13.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RGEN. Wells Fargo & Company began coverage on Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. Benchmark reissued a "hold" rating on shares of Repligen in a research note on Monday, August 5th. UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. Stephens reissued an "overweight" rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.